Invasive Aspergillosis (IA) is a major cause of morbidity and mortality in neutropenic and immunocompromised patients. Conclusive diagnosis of IA can be difficult, requiring fungal culture, histopathological examination along with consistent radiological findings; however an early diagnosis can be facilitated by positive PCR and antigen tests. Conversely, negative tests make the diagnosis less likely. The galactomannan antigen is an Aspergillus specific antigen released during the growth phase of Invasive Aspergillosis detectable in bronchoalveolar lavage (BAL) and serum samples of patients using the Bio-Rad Platelia™ Aspergillus Antigen Galactomannan Assay. The Platelia™ Aspergillus Antigen Assay is a one-stage immunoenzymatic sandwich microplate assay intended to detect galactomannan antigen in serum and BAL samples and assist in the diagnosis of IA. As false positive results may occur due to interfering substances such as beta-lactam antibiotics or laboratory environmental contaminants, it is generally accepted that two consecutive positive results are required for classification as a true positive for IA. With an approximate sensitivity of 70%, a negative test result does not rule out the diagnosis. In this poster we report the successful troubleshooting and implementation of the Platelia™ Aspergillus Antigen Assay at PathWest Fiona Stanley Hospital and a retrospective analysis of test numbers, percentage of positive samples, assay performance, result reproducibility, patient referral patterns and concordance between serum and BAL samples.